Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

shankar besta

  • Home
  • Author: shankar besta

5G to EVs – GaN technology drives innovation across multiple industries, reveals GlobalData’s Technology Foresights

Gallium Nitride (GaN), a wide bandgap semiconductor material, is emerging as a game-changer in high-performance electronics. Known for its high energy density, durability, and ability to operate at higher voltages and broader bandwidths, GaN is set to transform multiple sectors. Ranging from electric vehicles (EVs) in automotive to 5G in telecommunications, GaN materials are driving […]
Read more

JP Morgan and Houlihan Lokey top M&A financial advisers in North America in H1 2024, reveals GlobalData

JP Morgan and Houlihan Lokey were the top mergers and acquisitions (M&A) financial advisers in the North American region during the first half (H1) of 2024 by value and volume, respectively, according to the latest Financial Advisers League Table by GlobalData, a leading data and analytics company. An analysis of GlobalData’s Deals Database has revealed […]
Read more

AI revolutionizing more areas of medical than ever before, says GlobalData

Artificial Intelligence (AI) has emerged as a transformative force across various sectors, and healthcare is no exception. It is continually revolutionizing healthcare and can contribute to cost reduction and efficiency improvement in several ways. Within the realm of medical devices, AI is driving significant advancements, improving diagnostic accuracy, personalizing treatments, and enhancing patient outcomes. The […]
Read more

Synergistic safety profile could increase sublingual apomorphine competitiveness, says GlobalData

Sublingual apomorphine (SL-APO) is a dopamine agonist (DA) marketed by Bial under the brand name Kynmobi in several countries for the on-demand treatment of levodopa wear-off (OFF-episodes) that are not sufficiently controlled by levodopa “add-on” (adjunct) therapies. At the 10th Congress of the European Academy of Neurology (EAN) 2024, Dr. Diego Santos García presented a […]
Read more

Cross-border real-time payments make tangible progress as over 50% consumers use them, says GlobalData

Cross-border payments are becoming increasingly important to international economies. Around 63% of global consumers use international real-time payments (RTPs) services to send money to family and friends and 51% use them only to pay for goods and services, according to the 2024 Financial Services Consumer Survey* conducted by GlobalData, a leading data and analytics company. […]
Read more

Opicapone demonstrates efficacy in real-world clinical practice, says GlobalData

Opicapone is a catechol-O-methyltransferase (COMT) inhibitor marketed in several countries by either Amneal Pharmaceuticals or Bial, depending on region, under the brand name “Ongentys” for the treatment of levodopa wear-off in Parkinson’s disease (PD). At the 10th Congress of the European Academy of Neurology (EAN) 2024, Dr. Maria-Rosario Luquin and Dr. Lydia López Manzanares separately […]
Read more

South Korea radiosurgery systems market to see 6% CAGR through 2033, forecasts GlobalData

Brain tumors and associated neurological disorders pose a serious medical issue, impacting millions of people worldwide. These tumors interfere with normal brain activity, resulting in a range of symptoms such as headaches, seizures, and cognitive decline. This has driven the demand for advanced, minimally invasive treatments. In this context, South Korea’s radiosurgery systems market is […]
Read more

Safinamide outperforms rasagiline in efficacy, cost-efficacy, and forecasted sales, says GlobalData

Safinamide is a monoamine oxidase B (MAO-B) inhibitor marketed in several countries under the brand name Xadago by Newron Pharmaceuticals for the treatment of levodopa wear-off in Parkinson’s disease (PD). At the 10th Congress of the European Academy of Neurology (EAN) 2024, Dr. Ester Morales García presented a pharmacoeconomic report comparing safinamide to its competitor […]
Read more

Prioritized investments from pharma companies shaping competitive pipeline landscape of bronchiectasis, says GlobalData

Recent studies have allowed the unexplored field of bronchiectasis to be further investigated by shedding light on the mechanisms behind the disease’s pathophysiology. In recent years, bronchiectasis has garnered a significant amount of attention, with pharmaceutical companies prioritizing their investments in the development of promising pipeline agents to treat the disease through various mechanisms of […]
Read more

Healey platform data to pave phase III path for Prilenia’s pridopidine, says GlobalData

Developing disease-modifying treatments for amyotrophic lateral sclerosis (ALS), a rare and aggressive disease, has proven challenging. The high failure rate in ALS clinical trials is often attributed to the disease’s unclear etiology and complex pathophysiology. At the 10th Congress of the European Academy of Neurology (EAN) 2024, Prilenia Therapeutics presented promising results from the additional […]
Read more

Preventative treatment of chronic migraine will continue to evolve in short-term with anti-CGRP mAbs effectiveness, says GlobalData

OnabotulinumtoxinA (BoNT-A) and monoclonal antibodies against the calcitonin gene-related protein (anti-CGRP mAbs) have emerged as the first disease-specific preventative treatments to be approved for chronic migraine. At the 10th Congress of the European Academy of Neurology (EAN) 2024, Danilo Antonio Montisano, MD, presented real-world evidence findings from a retrospective, observational multicenter cohort study (RAMO) comparing […]
Read more
1 … 70 71 72 73 74 … 136